Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma

Trial Profile

Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Carfilzomib (Primary) ; TGR 1202 (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2016 According to a TG Therapeutics media release, status changed from not yet recruiting to recruiting.
    • 10 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top